Habib J. Dable - Jul 1, 2021 Form 4 Insider Report for ACCELERON PHARMA INC (XLRN)

Role: CEO and President, Director
Signature: /s/ Adam M. Veness, as attorney-in-fact for Habib J. Dable
Stock symbol: XLRN
Transactions as of: Jul 1, 2021
Transactions value $: -$9,178,942
Form type: 4
Date filed: 7/2/2021, 09:15 PM
Next filing: Nov 22, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLRN	Common Stock	Options Exercise	$2.03M	+57.8K	+58.72%	$35.04	156K	Jul 1, 2021	Direct	F1
transaction	XLRN	Common Stock	Sale	-$1.48M	-11.8K	-7.58%	$125.15	144K	Jul 1, 2021	Direct	F1, F2
transaction	XLRN	Common Stock	Sale	-$1.16M	-9.19K	-6.37%	$125.81	135K	Jul 1, 2021	Direct	F1, F3
transaction	XLRN	Common Stock	Sale	-$2.94M	-23.2K	-17.13%	$126.85	112K	Jul 1, 2021	Direct	F1, F4
transaction	XLRN	Common Stock	Sale	-$583K	-4.56K	-4.07%	$127.89	108K	Jul 1, 2021	Direct	F1, F5
transaction	XLRN	Common Stock	Sale	-$1.17M	-9.06K	-8.42%	$128.82	98.5K	Jul 1, 2021	Direct	F1, F6
transaction	XLRN	Common Stock	Options Exercise	$1.48M	+42.2K	+42.85%	$35.04	141K	Jul 2, 2021	Direct	F1
transaction	XLRN	Common Stock	Sale	-$3.69M	-29.1K	-20.72%	$126.69	111K	Jul 2, 2021	Direct	F1, F7
transaction	XLRN	Common Stock	Sale	-$1.46M	-11.5K	-10.28%	$127.51	100K	Jul 2, 2021	Direct	F1, F8
transaction	XLRN	Common Stock	Sale	-$204K	-1.59K	-1.59%	$128.21	98.5K	Jul 2, 2021	Direct	F1, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLRN	Option to Purchase Common Stock	Options Exercise	$0	-57.8K	-16.52%	$0.00	292K	Jul 1, 2021	Common Stock	57.8K	$35.04	Direct	F1, F10
transaction	XLRN	Option to Purchase Common Stock	Options Exercise	$0	-42.2K	-14.44%	$0.00	250K	Jul 2, 2021	Common Stock	42.2K	$35.04	Direct	F1, F10

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.41 to $125.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.42 to $126.41 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.42 to $127.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.44 to $128.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.53 to $129.14 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
F7	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.10 to $127.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4.
F8	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.13 to $128.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8) to this Form 4.
F9	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.13 to $128.77 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9) to this Form 4.
F10	The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of December 1, 2016 and the remaining shares vested in equal quarterly installments over the following three years thereafter.